Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Kyoto University is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 9, the average consequence score sits above the same-window beat average of 5.8.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Kyoto University is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 9, the average consequence score sits above the same-window beat average of 5.8. Each story carries 3 original sources on average, compared with 3.6 for the broader beat in this window. We currently track 1 Healthcare story that mention Sumitomo Pharma, all published on March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sumitomo Pharma. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Approval
Japan's Ministry of Health officially approves the therapy for clinical use.
Data Submission
Sumitomo Pharma submits trial data to Japan's PMDA for regulatory review.
Clinical Trial Launch
Kyoto University begins the first human clinical trial for iPS-derived Parkinson's treatment.
Nobel Prize Awarded
Shinya Yamanaka wins the Nobel Prize for the discovery of iPS cells.
Japan's Ministry of Health has granted regulatory approval for a groundbreaking stem-cell treatment for Parkinson's disease, marking the first time induced pluripotent stem cells (iPS) have been cleared for clinical use. The therapy, developed by Kyoto University and Sumitomo Pharma, aims to restore dopamine-producing neurons in the brain.
Source: bssnews.net · purdueexponent.org
Sumitomo Pharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
